Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its ...
Regeneron beats results estimates on demand for eczema treatment, eye drug
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...
Business Wire19h
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Regeneron: Investors In Panic Mode On Increased Eylea Fears
Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...
FiercePharma5d
Regeneron's Eylea HD makes progress but doesn't dent the momentum of Roche's Vabysmo
With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...
Drug Store News6d
Regeneron loses bid to block Amgen's launch of Eylea biosimilar
The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,215.00 at Royal Bank of Canada
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...
BioPharma Dive4d
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, ...
TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Zacks.com on MSN5d
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago. These figures ...